Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: A brief report

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 2, 2010, Pages 265-267

  Greene, Daniel P ^a   Ferriss, James Stuart ^b   Jazaeri, Amir A ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Cisplatin; Peritoneal carcinoma; Platinum desensitization failure; Platinum hypersensitivity

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; FAMOTIDINE; HYDROCORTISONE; HYDROXYZINE; LORATADINE; ONDANSETRON; PACLITAXEL; SALBUTAMOL; ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CLINICAL TRIAL; DESENSITIZATION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DYSPNEA; ERYTHEMA; FACE ERYTHEMA; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; LAPAROTOMY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PERITONEAL BIOPSY; PERITONEUM CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PRURITUS; SALPINGOOOPHORECTOMY; THORAX PAIN; VOMITING; OVARY TUMOR; PERITONEUM TUMOR; TREATMENT FAILURE;

AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TREATMENT FAILURE;

EID: 77953073623     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1159-6     Document Type: Article

References (15)

1. Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99(9):2467-2498
2. Everett EN, French AE, Stone RL, Pastore LM, Jazaeri AA, Andersen WA et al (2006) Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. Am J Obstet Gynecol 195(2):568-574 (discussion 574-576)
3. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34-43
4. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194-3200
5. Sliesoraitis S, Chikhale PJ (2005) Carboplatin hypersensitivity. Int. J. Gynecol. Cancer 15(1):13-18
6. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ et al (1991) Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 9(7):1138-1150
7. Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR (2002) Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 84(3):378-382
8. Rose PG, Fusco N, Smrekar M, Mossbruger K, Rodriguez M (2003) Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol 89(3):429-433
9. Robinson JB, Singh D, Bodurka-Bevers DC, Wharton JT, Gershenson DM, Wolf JK (2001) Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 82(3):550-558
10. McGuire WP, Ozols RF (1998) Chemotherapy of advanced ovarian cancer. Semin Oncol 25(3):340-348
11. Callahan MB, Lachance JA, Stone RL, Kelsey J, Rice LW, Jazaeri AA (2007) Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol 197(2):199e.1-199e.14 (discussion 199.e4-e5)
12. Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J, Robert J (2004) Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res 64(1):356-362
13. Zweizig S, Roman LD, Muderspach LI (1994) Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 53(1):121-122
14. Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J (2003) Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 21(24):4611-4614
15. Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV et al (2009) Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 123(6):1262-1267